Semaglutide's Role in Reducing Cardiovascular Risks

A study reported by a Cleveland Clinic physician in the New England Journal of Medicine reveals that semaglutide, typically used for diabetes and weight management, significantly reduces cardiovascular events by 20% in adults with established cardiovascular disease, obesity, or overweight, but without diabetes. The "SELECT" trial showed patients losing 9.4% of their body weight on average and improvements in cardiovascular risk factors.

Conducted internationally with over 17,000 participants, the study found that semaglutide effectively reduces the risk of death from cardiovascular causes, nonfatal heart attacks, or nonfatal strokes. For more details, visit the full article on Nature's website here.